data99
Iron
- Joined
- May 7, 2025
- Posts
- 41
- Reputation
- 9
I am 21 years old and have been dealing with a constellation of symptoms my entire life that never made sense in isolation. After getting bloodwork done and doing serious research everything pointed to the same root cause: a congenital partial 5-alpha reductase deficiency. I want to share this here because I think it is genuinely underdiagnosed and because the protocol I am running might be useful to others in a similar position.
Bloodwork
Total testosterone came back at 981 ng/dL. Free testosterone at 20.30 pg/mL, DHT came back at 0.44 ng/mL against a reference range of 0.33 to 1.20, placing me at approximately the 9th percentile.
To be clear about what this means: I have exceptional testosterone production by any standard, and my free testosterone is genuinely solid. The problem is the conversion step. The 5-alpha reductase enzyme that converts testosterone into DHT is underperforming significantly. I am producing plenty of the raw material and have barely produced dht since birth
What 5AR Deficiency Actually Does
DHT is not just relevant to hair loss discussions. It is the primary driver of male skeletal dimorphism, laryngeal development, prostate maturation, skin thickness and quality, and critically, neurosteroid synthesis through the production of allopregnanolone via the same enzymatic pathway. It also directly modulates dopamine receptor expression and tyrosine hydroxylase activity in the brain.
The symptoms I experienced throughout puberty and into adulthood are consistent with this deficiency across multiple organ systems simultaneously. Confirmed adolescent bone age by a dental professional with impaired Th1 immune function, and motivational and attentional difficulties consistent with reduced dopaminergic tone.
One of the more striking confirmations is a near complete substance non-response pattern. Alcohol produces no effect at any dose. Methamphetamine/desoxsyn at 5mg intranasal produced nothing. Phenibut at 1g produced nothing. Caffeine produces no stimulation. Semax and Selank produced no effect. It is a pattern entirely consistent with severe GABAergic hypofunction from chronic allopregnanolone deficiency and a dopamine synthesis bottleneck from insufficient DHT driven tyrosine hydroxylase expression. The GABA-A system is understimulated at the neurosteroid level, and the dopamine reserve is too shallow to respond to agents that work by releasing or conserving existing stores. It reads as a broken system but it is actually a starved one.
The lab note on my own DHT result recommended androstanediol glucuronide testing as a complementary marker of peripheral androgenicity, which would likely confirm tissue level DHT deficiency even more precisely than serum DHT alone.
Masteron
Masteron binds androgen receptors directly with high affinity as a DHT analog, it should provide the androgenic signal at the receptor level that my deficient 5AR enzyme fails to produce from testosterone. Unlike Proviron, which has relatively weak AR binding and works primarily through SHBG displacement, Masteron provides genuine direct androgenic activity at target tissues.
The goal is correcting a documented deficiency and allowing DHT dependent developmental processes that stalled during puberty to proceed. Bone maturation, neurological restoration, immune normalization, and soft tissue development are the targets. I will run a conservative therapeutic dose of 50-100mg.
Cerebrolysin
DHT supports dopaminergic neuron health through androgen receptor activation, and allopregnanolone from the same 5AR pathway is the brain’s primary endogenous GABA-A positive allosteric modulator. Years of deficiency in both has left the neurological substrate compromised. Cerebrolysin should provide exogenous neurotrophic support while Masteron begins restoring the hormonal signals those neurons were designed to receive.
Vorinostat
Vorinostat is an HDAC inhibitor. At low doses used intermittently it functions as an epigenetic tool rather than a chemotherapeutic agent.
Years of insufficient DHT signaling does not just mean switches were never flipped on and structure untouched by DHT, over time, chromatin around androgen-responsive genes closes down through histone deacetylation and methylation accumulation. These genes become physically inaccessible even when DHT is eventually provided. HDAC inhibition reopens this chromatin, allowing gene expression that would otherwise remain silenced despite adequate DHT levels.
This connects directly to PFS literature where AR nuclear localization is intact but downstream transcriptional activity is paradoxically low, suggesting blockage at the chromatin level. My situation differs from PFS in that I have never used 5AR inhibitors and have no pharmacologically induced AR dysregulation. But epigenetically silenced androgen response elements from years of insufficient signaling apply regardless of whether the deficiency was acquired or congenital.
Running vorinostat at 75mg once weekly, timed the day before Masteron injection to prime chromatin accessibility during peak DHT availability. 5 to 6 weeks on followed by 5 to 6 weeks off allows new expression patterns to consolidate rather than requiring continuous HDAC inhibition.
The Stack Summary
HGH at 4 IU daily currently running, with open plates, Masteron enanthate at therapeutic dose. Testosterone enanthate to maintain baseline while suppressed. HCG twice weekly to preserve testicular function. Cerebrolysin in 20 day course 10ML per day followed by a 10 day 20mg per day cortexin cycle. Vorinostat 75mg weekly timed to Masteron injection. BPC-157 and GHK-Cu for connective tissue support.
What I Am Tracking
Monthly photographs consistent lighting and angle. Bloodwork pre-cycle and at 6 to 8 weeks including DHT, E2, SHBG, CBC, lipids, liver enzymes, PSA and progesterone. Height measurement morning protocol. Subjective markers including energy, motivation, cognitive function and sleep quality logged weekly.
Partial 5AR deficiency producing low DHT in the context of normal or high testosterone is almost certainly underdiagnosed. The symptoms are diffuse and each one individually has alternative explanations. Bloodwork panels rarely include DHT unless specifically requested. The combination of high testosterone with low DHT is the diagnostic signature and it is simple to test for.
If anyone here has a similar presentation, the bloodwork is straightforward and the findings are actionable. Happy to discuss the rationale behind any part of this protocol.
Will update with bloodwork and subjective response as the cycle progresses.
Bloodwork
Total testosterone came back at 981 ng/dL. Free testosterone at 20.30 pg/mL, DHT came back at 0.44 ng/mL against a reference range of 0.33 to 1.20, placing me at approximately the 9th percentile.
To be clear about what this means: I have exceptional testosterone production by any standard, and my free testosterone is genuinely solid. The problem is the conversion step. The 5-alpha reductase enzyme that converts testosterone into DHT is underperforming significantly. I am producing plenty of the raw material and have barely produced dht since birth
What 5AR Deficiency Actually Does
DHT is not just relevant to hair loss discussions. It is the primary driver of male skeletal dimorphism, laryngeal development, prostate maturation, skin thickness and quality, and critically, neurosteroid synthesis through the production of allopregnanolone via the same enzymatic pathway. It also directly modulates dopamine receptor expression and tyrosine hydroxylase activity in the brain.
The symptoms I experienced throughout puberty and into adulthood are consistent with this deficiency across multiple organ systems simultaneously. Confirmed adolescent bone age by a dental professional with impaired Th1 immune function, and motivational and attentional difficulties consistent with reduced dopaminergic tone.
One of the more striking confirmations is a near complete substance non-response pattern. Alcohol produces no effect at any dose. Methamphetamine/desoxsyn at 5mg intranasal produced nothing. Phenibut at 1g produced nothing. Caffeine produces no stimulation. Semax and Selank produced no effect. It is a pattern entirely consistent with severe GABAergic hypofunction from chronic allopregnanolone deficiency and a dopamine synthesis bottleneck from insufficient DHT driven tyrosine hydroxylase expression. The GABA-A system is understimulated at the neurosteroid level, and the dopamine reserve is too shallow to respond to agents that work by releasing or conserving existing stores. It reads as a broken system but it is actually a starved one.
The lab note on my own DHT result recommended androstanediol glucuronide testing as a complementary marker of peripheral androgenicity, which would likely confirm tissue level DHT deficiency even more precisely than serum DHT alone.
Masteron
Masteron binds androgen receptors directly with high affinity as a DHT analog, it should provide the androgenic signal at the receptor level that my deficient 5AR enzyme fails to produce from testosterone. Unlike Proviron, which has relatively weak AR binding and works primarily through SHBG displacement, Masteron provides genuine direct androgenic activity at target tissues.
The goal is correcting a documented deficiency and allowing DHT dependent developmental processes that stalled during puberty to proceed. Bone maturation, neurological restoration, immune normalization, and soft tissue development are the targets. I will run a conservative therapeutic dose of 50-100mg.
Cerebrolysin
DHT supports dopaminergic neuron health through androgen receptor activation, and allopregnanolone from the same 5AR pathway is the brain’s primary endogenous GABA-A positive allosteric modulator. Years of deficiency in both has left the neurological substrate compromised. Cerebrolysin should provide exogenous neurotrophic support while Masteron begins restoring the hormonal signals those neurons were designed to receive.
Vorinostat
Vorinostat is an HDAC inhibitor. At low doses used intermittently it functions as an epigenetic tool rather than a chemotherapeutic agent.
Years of insufficient DHT signaling does not just mean switches were never flipped on and structure untouched by DHT, over time, chromatin around androgen-responsive genes closes down through histone deacetylation and methylation accumulation. These genes become physically inaccessible even when DHT is eventually provided. HDAC inhibition reopens this chromatin, allowing gene expression that would otherwise remain silenced despite adequate DHT levels.
This connects directly to PFS literature where AR nuclear localization is intact but downstream transcriptional activity is paradoxically low, suggesting blockage at the chromatin level. My situation differs from PFS in that I have never used 5AR inhibitors and have no pharmacologically induced AR dysregulation. But epigenetically silenced androgen response elements from years of insufficient signaling apply regardless of whether the deficiency was acquired or congenital.
Running vorinostat at 75mg once weekly, timed the day before Masteron injection to prime chromatin accessibility during peak DHT availability. 5 to 6 weeks on followed by 5 to 6 weeks off allows new expression patterns to consolidate rather than requiring continuous HDAC inhibition.
The Stack Summary
HGH at 4 IU daily currently running, with open plates, Masteron enanthate at therapeutic dose. Testosterone enanthate to maintain baseline while suppressed. HCG twice weekly to preserve testicular function. Cerebrolysin in 20 day course 10ML per day followed by a 10 day 20mg per day cortexin cycle. Vorinostat 75mg weekly timed to Masteron injection. BPC-157 and GHK-Cu for connective tissue support.
What I Am Tracking
Monthly photographs consistent lighting and angle. Bloodwork pre-cycle and at 6 to 8 weeks including DHT, E2, SHBG, CBC, lipids, liver enzymes, PSA and progesterone. Height measurement morning protocol. Subjective markers including energy, motivation, cognitive function and sleep quality logged weekly.
Partial 5AR deficiency producing low DHT in the context of normal or high testosterone is almost certainly underdiagnosed. The symptoms are diffuse and each one individually has alternative explanations. Bloodwork panels rarely include DHT unless specifically requested. The combination of high testosterone with low DHT is the diagnostic signature and it is simple to test for.
If anyone here has a similar presentation, the bloodwork is straightforward and the findings are actionable. Happy to discuss the rationale behind any part of this protocol.
Will update with bloodwork and subjective response as the cycle progresses.
